Adalimumab Stable Cell Line - CHO-K1

Adalimumab is a recombinant, fully human IgG1 monoclonal antibody developed as an inhibitor of tumor necrosis factor alpha (TNF-α), a cytokine involved in normal immune regulation and inflammatory responses. It was generated using phage-display technology and contains human-derived heavy- and light-chain variable regions together with human IgG1 constant regions. Adalimumab binds specifically to TNF-α and prevents the cytokine from interacting with the p55 and p75 TNF receptors on the cell surface, thereby reducing downstream inflammatory signaling. Adalimumab is used clinically for several chronic immune-mediated inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, juvenile idiopathic arthritis and non-infectious uveitis.

The Adalimumab Stable Cell Line - CHO-K1 is a recombinant production cell model engineered to express adalimumab in the widely used CHO-K1 host background. It can provide a consistent starting material for laboratory-scale antibody expression, upstream process development and optimization of parameters such as culture medium, feeding strategy, cell density and harvest time. Antibody recovered from conditioned culture medium may be used in downstream purification development and analytical studies covering identity, purity, aggregation, charge variants and glycosylation. The line may also support biosimilar research by supplying internally produced material for comparative binding and functional assays, including TNF-α binding, inhibition of TNF receptor signaling and cell-based neutralization studies. Researchers can additionally use it to examine production stability, product-quality variation and the relationship between culture conditions and antibody attributes.